PRT-060318

PRT-060318 is a novel, highly selective small molecule inhibitor of spleen tyrosine kinase (Syk), with an IC50 of 4 nM. Syk is a non-receptor tyrosine kinase involved in signaling pathways critical for immune cell activation, platelet function, and B-cell receptor signaling. By inhibiting Syk, PRT-060318 blocks downstream signaling events that contribute to diseases such as heparin-induced thrombocytopenia (HIT), diffuse large B-cell lymphoma (DLBCL), and acute lymphoblastic leukemia (ALL). Preclinical studies have shown that it prevents HIT antibody-mediated platelet activation and induces cell cycle arrest in sensitive DLBCL cells by blocking the G1-S transition. The drug was initially developed by Thomas Jefferson University and Portola Pharmaceuticals as a potential therapy for hematologic diseases[1][3][4][5][6][9].